Telmisartan + Cilnidipine: Quick Summary
Uses, benefits, side effects, dosage & important warnings
Drug Name
Telmisartan + Cilnidipine
Drug Class
Angiotensin II Receptor Blocker (ARB) + Calcium Channel Blocker (CCB)
Uses
Treatment of high blood pressure (hypertension)
Benefits
Helps lower blood pressure through two complementary mechanisms
Side Effects
Dizziness, headache, ankle swelling, flushing, fatigue and low blood pressure
Common Strengths
Strengths vary by manufacturer; combinations may include Telmisartan 40 mg + Cilnidipine 10 mg
How to Take
Usually taken once daily, as prescribed by your doctor
How It Works
Telmisartan blocks angiotensin II while cilnidipine relaxes blood vessels
Monitoring
Blood pressure, kidney function and potassium may require monitoring
Important
Do not change the dose or stop treatment without medical advice
⚠️ Important Interaction:
NSAIDs such as ibuprofen, diclofenac and naproxen may reduce the blood-pressure-lowering effect of telmisartan and may increase the risk of kidney problems in susceptible patients.
NSAIDs such as ibuprofen, diclofenac and naproxen may reduce the blood-pressure-lowering effect of telmisartan and may increase the risk of kidney problems in susceptible patients.
📉 Low Blood Pressure Warning:
Telmisartan and cilnidipine can both lower blood pressure. Dizziness, light-headedness or weakness may occur, particularly when treatment is started or the dose is increased.
Telmisartan and cilnidipine can both lower blood pressure. Dizziness, light-headedness or weakness may occur, particularly when treatment is started or the dose is increased.
🤰 Pregnancy Warning:
Telmisartan should not be used during pregnancy because medicines that act on the renin–angiotensin system can cause serious fetal harm. Consult a doctor immediately if pregnancy occurs during treatment.
Telmisartan should not be used during pregnancy because medicines that act on the renin–angiotensin system can cause serious fetal harm. Consult a doctor immediately if pregnancy occurs during treatment.